MAPT and Parkinson disease: Therefore, the main concern was to investigate the key drivers and molecular aspects of Aβ, tau, and α-syn, and targeting the protein-interacting partners responsible for toxic protein accumulation involved in the onset and progression of AD and PD may offer more therapeutic promise (Zhang et al. 2021a).